Patents by Inventor Ian Armitage
Ian Armitage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10745404Abstract: The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: GrantFiled: September 22, 2017Date of Patent: August 18, 2020Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
-
Patent number: 10017513Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.Type: GrantFiled: October 13, 2016Date of Patent: July 10, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
-
Publication number: 20180079755Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((4S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: ApplicationFiled: September 22, 2017Publication date: March 22, 2018Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
-
Patent number: 9802938Abstract: The present invention provides sulfamoylating reagents of formula RuN?—S(O)2X+, wherein X is a cyclic tertiary amine or a nitrogen-containing heteroaryl and Ru is an amine protecting group or hydrogen.Type: GrantFiled: November 25, 2014Date of Patent: October 31, 2017Assignee: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
-
Publication number: 20170190706Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.Type: ApplicationFiled: October 13, 2016Publication date: July 6, 2017Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
-
Publication number: 20150353555Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: ApplicationFiled: November 25, 2014Publication date: December 10, 2015Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
-
Publication number: 20150133460Abstract: This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.Type: ApplicationFiled: November 11, 2013Publication date: May 14, 2015Applicant: Millennium Phamaceuticals, Inc.Inventors: Ian Armitage, Abu J. Ferdous, Michael E. Bourland, Craig S.J. Boyle, Martin Ian Cooper, Marianne Langston
-
Publication number: 20150080573Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
-
Patent number: 8933225Abstract: Disclosed are processes and synthetic intermediates for the synthesis of compounds of formula (V) wherein the variables have the definitions contained herein. Such compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: GrantFiled: August 1, 2008Date of Patent: January 13, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hirotake Mizutani, Matthew Stirling, Lei Zhu
-
Publication number: 20140357622Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.Type: ApplicationFiled: January 9, 2014Publication date: December 4, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
-
Patent number: 8653064Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.Type: GrantFiled: February 15, 2011Date of Patent: February 18, 2014Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
-
Publication number: 20110245234Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.Type: ApplicationFiled: February 15, 2011Publication date: October 6, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
-
Publication number: 20100273808Abstract: This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma)glomerulosclerosis, fibrotic disease and inflammation.Type: ApplicationFiled: November 20, 2009Publication date: October 28, 2010Applicant: Millennium Pharmaceticals, Inc.Inventors: Ian Armitage, Michael E. Bourland, Craig J.S. Boyle, Martin Ian Cooper, Abu J. Ferdous, Marianne Langston
-
Publication number: 20090036678Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.Type: ApplicationFiled: August 1, 2008Publication date: February 5, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hirotake Mizutani, Matthew Stirling, Lei Zhu
-
Patent number: 6633574Abstract: The present invention is a method for acknowledgment of receipt of a message in a network, where the network includes a plurality of nodes. The method includes sending a message from a first node of the plurality of nodes destined for a second node of the plurality of nodes; setting a timer for the first node for receipt of an acknowledgment packet from the second node; determining if a wait acknowledge packet is received by the first node; and resetting the timer if the wait acknowledge packet is received by the first node. The present invention adds a wait acknowledge event to the state in the acknowledgment protocol which waits for an acknowledgement packet from the destination node. The wait acknowledge packet notifies the recipient that the message sent by the originating node has been received and forwarded. As long as the message is being properly forwarded to the next hop, wait acknowledge packets will continue to be sent to the originating node.Type: GrantFiled: March 17, 1999Date of Patent: October 14, 2003Assignee: LOYTEC Electronics GmbHInventors: Edward L Koch, Jeffrey Warren Scott, Thomas Ian Armitage